Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
HKEX:2269
Holding HK:2269?
Track your performance easily
2269 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$10.14 - HK$52.45
Previous CloseHK$11.52
Volume13.73M
Average Volume (3M)42.71M
Market Cap
HK$47.85B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.9
Beta1.35
Next Earnings
Mar 25, 2025EPS Estimate
HK$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares OutstandingN/A
10 Day Avg. Volume45,767,755
30 Day Avg. Volume42,710,202
Standard Deviation0.16
R-Squared0.35
Alpha0.00257
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)14.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.24Price Target Upside58.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Responds to U.S. House Draft Bill
PremiumCompany Announcements
WuXi Biologics Acquires Full Ownership of WuXi Vaccines
PremiumCompany Announcements
WuXi Biologics Announces 2024 Interim Results Call
PremiumCompany Announcements
Wuxi Biologics Reports Mixed Mid-Year Financials
PremiumCompany Announcements
WuXi Biologics Schedules Key Financial Review
PremiumCompany Announcements
WuXi Biologics Shareholders Approve All Resolutions
PremiumCompany Announcements
Wuxi Biologics Awards Restricted Shares to EmployeesBulls Say, Bears Say
Bulls Say
Market PositionWuXi Bio boasts 13% market share globally and 70% in China.
Revenue GrowthIf excluding COVID revenue, total revenue would increase by 37.7% YoY, and revenue from late-stage and CMO projects would surge by 101.7% YoY.
Share BuybackWuXi Bio has initiated a share repurchase plan with an aggregate value up to US$600mn, demonstrating management's confidence in the business.
Bears Say
Contract TerminationNo new US contracts when the bill is passed, existing US contracts to stop Jan 1st 2032.
EarningsAdj. net profit dropped -5%YOY to RMB 4.7bn, mainly due to investments in new facilities and digital infrastructure.
Regulatory RiskBIOSECURE Act may still get approved, which would restrict the business of WuXi Biologics in US within 6 months of implementation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
9.75% Mutual Funds
6.64% Other Institutional Investors
83.61% Public Companies and
Individual Investors
2269 FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was HK$10.14 and its highest was HK$52.45 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Currently, no data Available
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 25, 2025 which is in 186 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 21, 2024. The company reported HK$0.385 earnings per share for the quarter, missing the consensus estimate of HK$0.451 by -HK$0.066.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is HK$0.44.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,153,531,700 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.385 in its last earnings report, missing expectations of HK$0.451. Following the earnings report the stock price went down -2.906%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Among the largest hedge funds holding Wuxi Biologics (Cayman) Inc.’s share is Gilder Gagnon Howe & Co LLC.. It holds Wuxi Biologics (Cayman) Inc.’s shares valued at N/A.
---
Wuxi Biologics (Cayman) Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
6.75%
Trailing 12-Months
Asset Growth
7.57%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
2269 Company Deck
---
2269 Earnings Call
Q2 2023
0:00 / 0:00
---
2269 Stock 12 Month Forecast
Average Price Target
HK$18.24
▲(58.35% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Beam Therapeutics
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Editas Medicine
―
Best Analysts Covering 2269
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-23.57%
reiterated a buy rating 29 days ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -23.57% per trade.
---